Early data looks promising, but real-world use will determine whether the triple-action approach truly outperforms dual agonists
During your appointment, your healthcare provider will determine if tirzepatide is the right treatment option for you
Clinical trial results discussed in this article - STEP 1 (14.9% average body weight loss with semaglutide), SURMOUNT-1 (20.9% average body weight loss with tirzepatide), and SELECT (20% reduced risk of major cardiovascular events with FDA-approved Wegovy in a specific patient population) - relate to studied active ingredients and specific FDA-approved formulations in controlled trial populations and should not be interpreted as guaranteed outcomes for any individual patient or compounded formulation
Cost, insurance coverage, prior medication history, and side effect profile should all factor into the decision
Start losing weight If prescribed, GLP-1 medication is combined with nutrition guidance and ongoing medical monitoring
The proportion of participants attaining each intensive therapeutic goal over time is shown in Fig
.png&w=128&q=75)
